Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

AstraZeneca PLC

AZN ✓ COMPLIANT ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Mega Cap Analyst: BUY

Last Close

$160.17

▲ +0.33%

Market Cap $245.30B · Vol 388.57K

Key Metrics

P/E Ratio

23.64

FWD: 14.53

Market Cap

$245.30B

Mega Cap

Div Yield

2.04%

N/A

EPS Growth

N/A

YoY

RSI (14)

39.07

Momentum

Beta

N/A

vs Market

52W High

$212.70

24.70% below

52W Low

$153.43

4.39% above

Volume

388.57K

Avg 607.58K

P/B

5.92

Price-to-book

ROE

N/A

Return on equity

Free Float

96.56%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, AstraZeneca PLC (AZN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AZN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.79%

+0.89%

-12.13%

-17.14%

YTD

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$58.74B
Net Income	$10.23B
Revenue Growth (YoY)	+6.41%
Gross Margin	81.63%
Operating Margin	24.22%
Net Profit Margin	17.42%
ROE	N/A
ROA · ROIC	11.37% · 15.15%

P/E Ratio	23.64
Forward P/E (FY1)	14.53
PEG Ratio	0.62
P/S	4.94
P/B	5.92
P/FCF	32.40
EPS Growth	N/A
Outstanding Shares	1.55B

Technical Indicators

50-Day SMA	$166.78
200-Day SMA	$N/A
RSI (14)	39.07
Beta	N/A
52-Week High	$212.70
52-Week Low	$153.43

Volume Today	388.57K
Avg Daily Volume (30D)	607.58K
Relative Volume	0.64x
Volatility (10D)	19.89
Volatility (30D)	30.31
Free Float	96.56%

Analyst Consensus

BUY

Current Price $160.17

Mean Target $215.89

52W Low$153.43 52W High$212.70

Current

Target

$153.43 $212.70

Current Analyst target

+34.79% upside potential · 23 analysts

Identifiers

ExchangeNYSE

FIGIBBG001SB80N8

ISINGB0009895292

CountryUK

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company -0.65% JNJ Johnson & Johnson -0.29% ABBV AbbVie Inc. +0.83% NVS Novartis AG -0.23% NOVN.S Novartis AG -0.09%

Company Profile

AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.